Mental Health and Academic Performance in COVID-19 (PANDEMIC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04420416 |
Recruitment Status :
Recruiting
First Posted : June 9, 2020
Last Update Posted : July 28, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Depression, Anxiety | Other: Survey |
Study Type : | Observational |
Estimated Enrollment : | 720 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Official Title: | dePression, Anxiety, aNd acaDemic pErforMance In Covid-19: PANDEMIC Study. |
Actual Study Start Date : | April 1, 2020 |
Estimated Primary Completion Date : | July 30, 2020 |
Estimated Study Completion Date : | July 30, 2020 |

- Other: Survey
The investigators will use the Spanish language validated version of the Academic Self-Concept Scale (ASCS), the Patient Health Questionnaire-9 (PHQ-9) depression screening scale, and the General Anxiety Disorder-7 (GAD-7) screening scale. Additionally, the sample will be asked about their gender, age, preference of teaching modality, and finally, if the participants have perceived a change in their performance or any change in their grades.
- Academic Self-Concept Scale Score [ Time Frame: up to 3 months ]This scale will explore the effort and confidence of the participants. The minimum score for each facet is 10, and the maximum score is 70.
- PHQ-9 Score [ Time Frame: up to 3 months ]This inventory will be used to identify the presence and intensity of depressive disorders. The minimum score is 0, and the maximum score is 27.
- GAD-7 Score [ Time Frame: up to 3 months ]This questionnaire will be used to evaluate the presence and intensity of anxiety disorders. The minimum score is 0, and the maximum score is 21.
- Preference of teaching method [ Time Frame: up to 3 months ]Students' preference of classroom or online classes.
- Self perceived academic performance [ Time Frame: up to 3 months ]Students' perception of changes in their academic performance: got better, worse, or stayed the same.
- Academic grades changes [ Time Frame: up to 3 months ]Students' perception of changes in their grades: got better, worse, or stayed the same.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- > 18 years
- Students of any undergraduate or graduate course who are attending their semester online
Exclusion Criteria:
- Students who are not attending an online course
- Students who are not registered in a university undergraduate or graduate course.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04420416
Mexico | |
Instituto Mexicano del Seguro Social | Recruiting |
Guadalajara, Jalisco, Mexico, 44329 | |
Contact: Alejandro Gonzalez Ojeda, PhD +52333170060 ext 31309 avygail5@gmail.com |
Responsible Party: | GONZALEZ-OJEDA ALEJANDRO, Investigador Titular D, Instituto Mexicano del Seguro Social |
ClinicalTrials.gov Identifier: | NCT04420416 |
Other Study ID Numbers: |
Mental01 |
First Posted: | June 9, 2020 Key Record Dates |
Last Update Posted: | July 28, 2020 |
Last Verified: | July 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | There is no plan of making individual participant data available. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
COVID-19 Depression Anxiety Public health Academic performance |
Depression Depressive Disorder Anxiety Disorders |
Behavioral Symptoms Mood Disorders Mental Disorders |